| Drug | Number of patients taking drug [n = 9] | Baseline monitoring carried out (%) | On-going monitoring carried out (%) | Drug specific monitoring carried out (%) |
| Amikacin | 6 | 58% | 85% | 91% |
| Capreomycin | 1 | 81% | 85% | 100% |
| Clofazamine | 3 | 71% | 90% | 55% |
| Co-amoxiclav | 3 | 38% | 77% | N/A* |
| Cycloserine | 9 | 61% | 82% | 91% |
| Ethambutol | 4 | 64% | 84% | 52% |
| Linezolid | 4 | 66% | 82% | 48% |
| Moxifloxacin | 6 | 72% | 84% | 17% |
| PAS | 4 | 53% | 82% | 94% |
| Prothionamide | 8 | 60% | 83% | 53% |
| Pyrazinamide | 3 | 46% | 71% | N/A* |
| Rifampicin | 1 | 69% | 72% | N/A* |
↵*Drugs did not require specific monitoring, according to drug monographs.